EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Tacrolimus in pediatric patients with Henoch-Schönlein purpura nephritis: Target concentration range

Fashuang Li, Huiying Li, Linbo Li, Lilin Zhang

Archives de Pédiatrie · 2025

DOI: 10.1016/j.arcped.2025.09.002 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Archives de Pédiatrie, 2025. Verfasst von Fashuang Li und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Kunming Children's Hospital, Yunnan, China. Hauptthemen laut MEDLINE: Tacrolimus, IgA Vasculitis, Immunosuppressive Agents, Nephritis. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Major Science and Technology Projects in Yunnan Province, Kunming Science and Technology Bureau, Science and Technology Planning Project of Shenzhen Municipality.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: This study seeks to establish the therapeutic reference range for tacrolimus blood concentrations in pediatric patients diagnosed with Henoch-Schönlein purpura nephritis (HSPN) and to evaluate the factors influencing tacrolimus pharmacokinetics in this population. METHODS: Receiver operating characteristic (ROC) curve analysis was utilized to determine the optimal therapeutic threshold for tacrolimus concentration. Comparative analyses were conducted to assess clinical efficacy and adverse event profiles across four groups of tacrolimus concentrations [Group A( 0.05), indicating limited predictive performance. Although no significant differences in adverse event rates were observed among the four groups, Group D displayed a notably higher incidence of nephrotoxicity relative to the other groups. Multivariate linear regression analysis identified serum creatinine level as a significant determinant of tacrolimus concentration (P < 0.05). CONCLUSION: In pediatric patients with HSPN in China, maintaining tacrolimus trough concentrations within the therapeutic range of 3-5 ng·mL-1 has been demonstrated to achieve optimal therapeutic efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TacrolimusIgA VasculitisImmunosuppressive AgentsNephritisHumansChildMaleFemaleChild, PreschoolAdolescentROC CurveRetrospective StudiesReference Values

Stichwörter der Autor:innen

Henoch-Schönlein purpura nephritisInfluencing factorsPediatricTacrolimusTarget trough concentration

Substanzen

TacrolimusImmunosuppressive Agents

Autor:innen und Institutionen

  • Department of Pharmacy, Kunming Children's Hospital, Yunnan, China.
  • Department of Pharmacy, Kunming Children's Hospital, Yunnan, China. Electronic address: 2064790166@qq.com.

Förderung

  • Major Science and Technology Projects in Yunnan Province
  • Kunming Science and Technology Bureau
  • Science and Technology Planning Project of Shenzhen Municipality

Zitieren

APA

Li, F., Li, H., Li, L., & Zhang, L. (2025). Tacrolimus in pediatric patients with Henoch-Schönlein purpura nephritis: Target concentration range. Archives de Pédiatrie. https://doi.org/10.1016/j.arcped.2025.09.002

Vancouver

Li F, Li H, Li L, Zhang L. Tacrolimus in pediatric patients with Henoch-Schönlein purpura nephritis: Target concentration range. Archives de Pédiatrie. 2025. doi:10.1016/j.arcped.2025.09.002

BibTeX
@article{Li2025,
  author = {Li, Fashuang and Li, Huiying and Li, Linbo and Zhang, Lilin},
  title = {Tacrolimus in pediatric patients with Henoch-Schönlein purpura nephritis: Target concentration range},
  journal = {Archives de Pédiatrie},
  year = {2025},
  doi = {10.1016/j.arcped.2025.09.002}
}
Kostenlos starten →